Background: Patients suffering from diabetes mellitus (DM) may experience an increased risk of cancer; however, it is not certain whether this effect is due to diabetes per se.
INTRODUCTION

Rationale
The CAncer Risk and INsulin analoGues (CARING) project aims to assess the possible carcinogenic effect of *Address correspondence to this author at the Department of Endocrinology and Internal Medicine (MEA), Aarhus University Hospital, Tage Hansens Gade 2, 8000 Aarhus C, Denmark; Tel: 0045 78467682; Fax: 0045 78467684; E-mail: jakolind@rm.dk insulin. As part of this project evaluation of the background risk of developing cancer in diabetes patients was performed in this systematic review and meta-analysis.
Diabetes Mellitus is associated with increased morbidity and mortality. Diabetes is the 8 th leading cause of mortality in high-income countries; whereas colorectal and breast cancer are the 7 th and 10 th leading causes, respectively [1] . Associations between diabetes and cancer have already been established for specific cancer sites in several meta-analyses , however it is not known whether the observed associations were due to diabetes per sé or caused by competing risks.
Associations between diabetes and cancer have been established by several meta-analyses including only studies of an observational design (case control and/or cohort). All meta-analyses reporting a significant increased risk among diabetes patients for pancreatic cancer between 1.8 to 2.1 [2] [3] [4] and liver cancer between 1.8 to 3.6 [5] [6] [7] [8] 24] . Subgroup analyses stratified by gender or statistical adjustment for Body Mass Index (BMI), smoking and alcohol did not influence the risk for pancreatic cancer [2] . However, results were conflicting on whether a duration of diabetes of 10 years was associated with an increased risk of pancreatic cancer [2, 3] , while duration of diabetes appeared not to influence risk of liver cancer [5] . Furthermore, diabetes treatment modulated the risk of liver cancer with greater risk estimates for insulin or sulfonylurea users than for metformin users [5] . Several observational studies have examined the relationship between diabetes and gastrointestinal cancers. Results were conflicting in the meta-analyses on gastric cancer [15, 16] , while an increased risk of esophageal cancer was reported [13] . In addition, diabetes has been associated with an increased risk of colorectal cancer [17] [18] [19] [21] [22] [23] after adjustment for BMI and smoking [20] . Both endometrial cancer [7] and breast cancer [25] [26] [27] [28] were reported to be increased in diabetes, while prostate cancer was found to be decreased in men with diabetes by 10 % [9, 10] . The association with prostate cancer was independent of BMI [10] . Diabetes was also associated with increased risk of kidney cancer [11] and bladder cancer [12] ; however this last association was not significant when using estimates adjusted for BMI due to wider confidence intervals. Last of all an increased risk among diabetes patients for non-Hodgkin lymphoma and leukemia but not multiple myeloma has also been reported in a meta-analysis [14] .
It is uncertain whether the relationship between diabetes and cancer is direct (e.g., due to hyperglycemia), whether diabetes is a marker of underlying biologic factors that alter cancer risk (e.g., insulin resistance and hyperinsulinemia), or whether the association between diabetes and cancer is indirect and due to common risk factors such as obesity. Duration of diabetes has been found to be of importance in the development of cancer among insulin using type 2 diabetes (T2D) patients [29] ; however whether cancer risk was influenced by the duration of diabetes is a critical and complex issue and may be complicated further by the multidrug therapy often necessary for diabetes treatment. The incidence of cancer increases with age, and as age increases with duration of diabetes, this may confound the association between diabetes and cancer. However, an association between diabetes and cancer was present for several cancer sites. Few studies take into account duration of diabetes, medication use or age of the participants. Furthermore, a meta-analysis reported an association between obesity and several cancer types including colorectal, kidney, breast and endometrial cancer, and also an independent association between obesity and T2D [30] . Therefore, it is important both to take obesity into account and to distinguish between type 1 diabetes (T1D) and T2D, which have not been done in previous reports. Except from Ge et al. [16] (using three databases), none of the metaanalyses described in the introduction have used more than two databases in their search (Medline at PubMed and Embase/ Medline at PubMed and Cochrane database of systematic reviews), and many only used Medline at PubMed leaving them with a possible publication bias.
Objectives
In an attempt to evaluate the risk of cancer in diabetes patients and taking possible determinants into account this thorough systematic review and meta-analysis was conducted. The primary objective was to study the effects of diabetes per sé, by collating observational studies that compared diabetes patients to non-diabetes. A secondary objective was to examine the effects that type of diabetes, body weight, metabolic control, diet as well as study design had on the risk of cancer.
METHODS
Protocol and Registration
The systematic review and meta-analysis was developed according to the Cochrane Collaboration (http://www.cochr ane.org/training/cochrane-handbook), and PRISMA guidelines [31] (http://www.prisma-statement.org/) and was registered on PROSPERO (http://www.crd.york.ac.uk/prospero/) with the registration number: CRD42012002310.
Eligibility Criteria
The eligibility criteria for the studies were those studies that evaluated the association between diabetes and cancer (incidence, odds or prevalence) as the outcomes. Studies evaluating solely cancer mortality were excluded. The studies needed to compare diabetes patients with a nondiabetes reference group. All types of observational study designs (e.g. case control, cohort and cross-sectional studies) were included. Studies assessing the effect of a specific intervention compared to no intervention were excluded. Studies only published as conference abstracts were excluded. Studies were not excluded due to language or publication year.
Information Sources
The systematic literature search included 7 databases: Medline at PubMed, Embase, Cinahl, Bibliotek.dk, Cochrane library, Web of Science, and SveMed+. The first search was performed 11 th of January 2012, and updated with the last search on the 9 th November 2012. Additional studies were added after assessment of the reference list in meta-analyses and reviews found in the search. Furthermore, studies were retrieved from the literature search of a systematic review of insulin use and cancer risk also performed by the CARING project group (PROSPERO registration number: CRD42012002428).
Search
The search terms included: "Diabetes mellitus", "diabetes", "Neoplasms", "cancer", "Prospective study", "statistics", "cancer statistics", and "Risk of cancer". Other search terms such as statistics and cancer statistics were also used but gave to few results and were not used as the final result. The search was performed using the thesaurus if available in the respective databases. Limitations were used to refine the search if available in the databases ("biochemistry", "cancer", "physiology and endocrinology", "cochrane review", "controlled clinical trial", "systematic review", "clinical trial", "randomized controlled trial", "review", "meta-analysis"), qualifiers ("analysis", "blood", "classification", "epidemiology", "statistics and numerical data"), categories ("endocrinology metabolism", "oncology") and research areas ("endocrinology metabolism", "oncology", "biochemistry molecular biology"). Search terms, limitations, qualifiers, categories and research areas used differently by database dependent on the functions available at the database. The search from Embase is listed below. The results from #9 in the Embase search were used in this study. 
Study Selection and Data Collection Process
Studies were assessed for eligibility using the criteria above. Reviewer one (JSL) performed the literature search in collaboration with a research librarian. Reviewer one and reviewer two (ØK) added additional studies from the insulin and cancer literature search, and studies were added from other meta-analyses and reviews by reviewer one. Reviewer one and reviewer two examined all studies by screening title and abstract. Studies passing this round were retrieved in full text and independently assessed for eligibility by reviewer one and two. Records for which both reviewers agreed on were included in the systematic review and meta-analysis. Disagreement were settled by discussion or if necessary by reviewer three (PV). No supplementary data were collected from the authors of the studies.
Data Items
From each study information was extracted on cancer risk (prevalence ratio, risk ratio, odds ratio, incidence ratio, standardized incidence ratio, hazard ratio), cancer site, patient characteristics including type of diabetes mellitus (type 1, type 2 or unspecified), age (mean/median/not reported), duration of diabetes (mean/median/not reported), HbA1c level (mean/median/not reported), BMI (mean/median/not reported), follow up years (mean/median/not reported), and on study design (case control/cohort/cross-sectional), population (population based/hospital based), confounders used to adjust for, and specific comorbidities. Data was extracted by reviewer one and validated by reviewer two. Any disagreement was solved by discussion. Studies that used the same study population as other studies were excluded by reviewer one and reviewer two to secure that no duplicate estimates were used in the meta-analysis.
Risk of Bias in Individual Studies
The risk of bias in individual studies was assessed using the Newcastle Ottawa Scale (NOS) [32] . The user-defined items required in the NOS score were defined as follows: age was the most important adjustment factor; the exposed patients in cohorts should be representative of the average "diabetic population", minimum follow up time as 5 years, and loss to follow-up less than 10%. A scale modified for cross-sectional studies were produced for the quality score of these studies (the NOS are available in the Supplementary Material 1).
Reviewer one and reviewer two scored the studies based on the NOS. If the reviewers scored differently it was solved by discussion and if this was not possible reviewer three decided the score.
Summary Measures and Synthesis of Results
Prevalence ratios, risk ratios (RR), odds ratios, incidence ratios, standardized incidence ratios (in general standardized by age and sex using a reference population from same cancer registry, same district or the entire population of a country) and hazard ratios including 95% CI comparing the risk of cancer in diabetes patients compared to a nondiabetes group were the summary measures. A random effects model, Der Simonian and Laird, was used in all analyses [33] . The random effects model considers both in study and between study variability. As all the measures are common effect estimates the pooled result can be interpreted as a risk ratio. Only estimates based on two or more populations were included in the meta-analysis. 
Risk of Bias Across Studies
Risk of publication bias across studies was assessed using Egger's regression analysis [34] in STATA 8.
Additional Analyses
Subgroup analyses were performed for cancer sites, study design and gender. Meta-regression analyses were performed to assess whether any of the extracted characteristics were determinants of cancer risk. For the meta-regression the covariates were coded as follows: gender (0 = female, 1 = male), diabetes type (0 = unspecified, 1 = T1D, 2 = T2D), study design (0= case control, 1 = cohort, 2 = crosssectional), source (1=population, 2=hospital, 3=other), adjustment factor (0= no age adjustment, 1= age + other, 2= BMI / obesity / waist hip ratio + other, 3 = Age, BMI +other, 4= Age, Sex, BMI, Smoking + other) 5= Age, BMI and duration of diabetes), diabetes ascertainment (1 = registry, 2 = questionnaire / interview, 3 = biochemical analysis or criteria, 4 = other), cancer ascertainment (1 = registry with confirmation, 2 = questionnaire / interview, 3 = pathology / histology/ imaging / criteria, 4=other) and NOS (0-9). Other covers mixed ascertainments and other types of ascertainment. Age (years) was calculated as the difference of the age between cases and controls in case control studies and between diabetes cohort and non-diabetes cohort in cohort studies. The same applied for BMI (kg/m 2 ). Sub analysis for age and BMI were performed by study design. For age, BMI and follow up years only mean or median estimates were used in the meta-regression. Age BMI and follow up years where treated as numerical outcomes in the meta-regression, whereas other variables were treated as categorical outcomes. Only analyses with the use of three or more populations were included in the meta-regression. HbA1c and duration of diabetes were extracted from the records, but too few values (two studies report on mean HbA1c and 4 studies report mean duration of diabetes) were available to perform a meaningful analysis.
RESULTS
Study Selection
The selection process is depicted in Fig. (1) . 1,849 records were identified from the database search. An   Fig. (1) . PRISMA flow diagram. additional 172 records were identified from the reference list in meta-analyses and reviews identified in the search, and from the systematic literature search (PROSPERO registration number: CRD42012002428) on insulin and cancer also performed by the CARING group. In total 2,021 records were identified. The RefWorks (RefWorks, RefWorks-COS, ProQuest RefWorks 2.0, 2010) functions exact duplicates and close duplicates were used to remove duplicates. In total 1,785 unique records were retrieved. Screening by title and abstract by reviewer one and two excluded 1,534 records, thus 251 records remained. Of these records, 193 records (106 cohort studies, 80 case-control studies, 6 cross-sectional studies and 1 combined casecontrol and cross-sectional study [35] ) were included in the systematic review, while 66 records were excluded after assessing for full text eligibility (21 were excluded due to duplicate data with other studies, 3 were excluded due to lack of data, 11 were excluded because diabetes was not the exposure, 4 were excluded because they did not compare to a non-diabetes reference, 1 record was excluded due to interventional study design and 16 studies were excluded because the outcome was not incident or prevalent cancer ). 190 records were included in the meta-analysis. Two studies were excluded from this analysis due to lack of information on the outcome to an extent that made analysis impossible [36, 37] . One study was the only to report on head and neck cancer [38] and was not included in the meta-analysis.
Study Characteristics and Risk of Bias within Studies
Tables 1-3 present the study characteristics and NOS score of the included studies in the systematic review for cohort and cross-sectional studies and case-control studies, respectively. Additional study information is available in the electronic Supplementary Material 2. The study quality ranged from as low as 3 to the highest score of 9, although most of studies (84%) were of fair quality (NOS 6-9). NOS is part of the meta-regression presented below.
Results of Individual Studies
The results of the individual studies are presented in the electronic Supplementary Material 3. Stott-Miller et al. [38] was the only study specifically addressing head and neck cancer, and they presented an odds ratio of 1.09 (0.95-1.24) for head and neck cancer for diabetes patients compared to a non-diabetes reference. Thus it was not used in the included in the meta-analysis. Table 4 presents the pooled analysis of the studies and the pooled results are depicted in Fig. (2) . All available cancer types were included. Diabetes patients have a significant increased risk of any cancer, biliary and gallbladder cancer, bladder cancer, bone cancer, breast cancer, colon cancer, colorectal cancer, rectal cancer, esophagus cancer, liver cancer, lung cancer, leukemia, lymphoma, non-Hodgkin lymphoma, pancreas cancer, kidney cancer, small intestine cancer, stomach cancer and thyroid cancer. Female diabetes patients were also at increased risk for breast, cervix, endometrial and ovary cancer. However; diabetes patients have a lower risk of prostate cancer and skin cancer than non-diabetic subjects. In these analyses, only bone and thyroid cancer did not display significant heterogeneity by chi square testing. For the remaining cancer types (testes cancer, myeloma, melanoma, lung, larynx, bone cancer and nervous system cancers) no significantly in-or decreased association between diabetes patients and non-diabetes was observed.
Synthesis of Results
Subgroup analyses were performed on study design (cohort/case control) and gender (male/female). Figs. (3) (4) (5) (6) illustrates the results of the analyses. Cohort studies found among diabetes patients an increased risk of any, biliary, breast, cervix, colon, colorectal, endometrial, kidney, liver, ovary, pancreas, rectum, small intestine, stomach, and thyroid cancer, as well as leukemia, all lymphomas, and nonHodgkin lymphoma, while the risks of prostate, and skin cancer were decreased. Case control studies show similar results as cohort studies including an increased risk of larynx cancer; however the pooled estimates for cervix-, kidney-, leukemia-, non Hodgkin lymphoma-, prostate-, stomach-, and thyroid cancer were without significance. Males with diabetes were at an increased risk of all cancers combined, biliary, colon, colorectal, kidney, liver, pancreas, rectum, small intestine, and thyroid cancer and leukemia, while the risk of prostate cancer was decreased. Females with diabetes were at an increased risk of any, breast, cervix, colon, colorectal, endometrial, kidney, leukemia, liver, ovary, and pancreas cancer.
Risk of Bias Across Studies
Egger's regression test revealed significant publication bias for any cancer (p=0.048), colorectal cancer (p=0.024), esophagus cancer (p=0.022), larynx cancer (p=0.041), lymphoma (p=0.041) and lung cancer (p=0.015). The graphical depictions of the bias test for these cancer types are available in the electronic Supplementary Material 5. All these publication biases have a positive intercept value indicating higher effect size in smaller studies. None of the other cancer types displayed publication bias. Table 5 present results from the meta-analysis. These results reflect the effect modification of the variables on the measured cancer risk in the studies. A positive determinant increases the risk ratio for cancer among diabetes patients, whereas a negative determinant decreases the risk ratio for cancer among diabetes patients. The coefficient is the betacoefficient from the regression. Not all variables were available for all of the specific cancer analyses. In the following only specific parts will be highlighted. Male gender was a significant negative determinant of the risk of leukemia in (β = -1.52) and reduces the risk of leukemia among diabetes patients. Age difference may both be a significantly positive, negative and no determinant depending on cancer type. BMI differences was no determinant of breast-, colorectal-, endometrial-, kidney-, liver-, pancreas-, and prostate-cancer risk, however it was a negative determinant (β = -0.08) for lung cancer. Diabetes type was only a significantly negative determinant in colon Age and BMI are provided by means if nothing else is specified. Follow up years are provided by means, medians or follow up period. *Comobidity in the population examined. Body mass index (BMI), diabetes mellitus (DM), digital rectal examination (DRE), general practicioner (GP), hepatitis C virus (HCV),. Total: For the whole group or the complete study period. Age and BMI are provided by means if nothing else is specified. Follow up years are provided by means, medians or follow up period. *Comobidity in the population examined. Body mass index (BMI), diabetes mellitus (DM), digital rectal examination (DRE), general practicioner (GP), hepatitis C virus (HCV),. Total: For the whole group or the complete study period.
Meta-Regression
Non Hodgkin lymphoma (NHL), Nervous system (Brain), RR (risk ratio) Fig. (2) . Plot of the pooled analysis of all populations of the risk of cancer among diabetes patients compared to a non-diabetes population.
Non Hodgkin lymphoma (NHL), Nervous system (Brain), RR (Risk ratio) Fig. (3) . Plot of the pooled analysis of all cohort populations of the risk of cancer among diabetes patients compared to a non-diabetes population.
Non Hodgkin lymphoma (NHL), RR (Risk ratio) Fig. (4) . Plot of the pooled analysis of all case control populations of the risk of cancer among diabetes patients compared to a non-diabetes population.
Non Hodgkin lymphoma (NHL), RR (Risk ratio)
Fig. (5).
Plot of the pooled analysis of all populations only consisting of males of the risk of cancer among diabetes patients compared to a non-diabetes population.
Non Hodgkin lymphoma (NHL), Nervous system (Brain), RR (Risk ratio) Fig. (6) . Plot of the pooled analysis of all populations only consisting of females of the risk of cancer among diabetes patients compared to a non-diabetes population.
DISCUSSION
Summary of Evidence
This systematic review and meta-analysis confirms the previous findings of an increased cancer risk among diabetes patients. The addition of several databases to the literature search compared to previous meta-analyses did not change the associations previously found. Diabetes patients were especially susceptible to liver cancer (RR= 2.13; 95% CI 1.81-2.50), pancreas cancer (RR= 2.21; 95 %CI 1.93-2.54), and endometrial cancer (RR= 1.81; 95% CI 1.63-2.01). In addition, new cancer sites have been investigated: risks of cervix (RR=1.34; 95% CI 1.10-1.63)), ovary cancer (RR= 1.20; 95% CI 1.03-1.40), and small intestinal cancer was reported (RR=1.47; 95 % CI 1.03-2.11) were also slightly increased in diabetes patients. In addition female diabetes patients were at increased risk of breast (RR= 1.13 95 % CI 1.07-1.18). Thus females with diabetes were at increased risk of gender specific and hormone related cancers compared to their non-diabetic counterparts. However, male diabetes patients seem to be have a reduced risk of prostate cancer (RR= 0.85; 95% CI 0.80-0.91), which support the previous findings [9, 10] . Furthermore, our findings support an increased risk of gastric and stomach cancer (RR=1.13; 95 % CI 1.02-1.24), whereas former reports have been conflicting [15, 16] . An elevation in thyroid cancer (RR=1.27; 95 % CI 1.12-1.43) was also present among diabetes patients. A single study reported on head and neck cancer, which found Significance is indicated by bold. Number of populations covers the number of populations used in the pooled analysis, this may not be the same as the number of records used in the analysis, thus some records have multiple populations. RR: Risk ratio, CI: Confidence interval. * In this category studies estimating the risk of biliary tract extra-and intra hepatic, gallbladder cancer and cholangiocarcinoma were pooled ** In this category estimates of lymphoma, Hodgkin lymphoma and combined estimates of lymphoma including NonHodgkin lymphoma were pooled. *** Some estimates used in skin cancer cover both non-melanoma skin cancer and melanoma.
that cancer risk, was not significantly increased among diabetes patients [38] .
Neither study design nor gender appears to modulate the overall increase in cancer risk among diabetes patients.
Duration of diabetes was not available for analyses, which may influence results. The increased risk of pancreas cancer in diabetes may be due to cancer diagnosis in the following years after diabetes diagnosis, where the risk especially was 
Biliary tract and gall bladder 0 (7) 0 (7) - (25) + ( +: statistically significant positive determinant, -: statistically significant negative determinant, 0: no statistical significance, blank: could not be performed and not included in the meta-regression). The () marks how many populations were available for the regression results. Number of populations covers the number of populations used in the pooled analysis, this may not be the same as the number of records used in the analysis, thus some records have multiple populations. Some estimates used in skin cancer cover both non melanoma skin cancer and melanoma. Gender, diabetes type, source, diabetes ascertainment, cancer ascertainment, adjustment and NOS were all coded as categorical values, * regression analysis included age, gender, NOS and BMI if available. £ regression analyses included study design, source, diabetes ascertainment, adjustment factors and cancer ascertainment. ** Regression performed without BMI. *** Regression performed without diabetes type. BMI: Body Mass Index, NHL: Non Hodgkin lymphoma, NOS: Newcastle Ottawa Scale score. C: significance only applies to cohort studies not case control studies. CC: significance only apply to case control studies. Variables were entered in the categories as described in the methods section.
increased [207] . Normalization of the cancer risk occurs10 years after diabetes diagnosis [207] , and may be a result of detection bias or indicate that diabetes diagnosis was a symptom of pancreatic cancer. Johnson et al. [131] investigated time dependent factors in cancer risk and diabetes and conclude that the increased cancer risk may be due to increased ascertainment after diabetes diagnosis.
Obesity may be a confounder when assessing cancer risk in diabetes patients [30] . This was not supported by the meta-regression conducted. BMI was a negative determinant for risk of lung cancer, while no other cancer risk was determined by BMI; hence effect modification was only apparent when looking at lung cancer. When looking at the adjustment performed by the studies in the meta-analysis; adjustment by BMI and age were positive determinants of cancer risk in comparison to adjustment for age alone. These results indicate that obesity among diabetes patients was not an effect modifier on the risk of cancer in diabetes, and obesity may not be the explanation for the increased cancer risk for the types rectum, thyroid, biliary tract and gallbladder, ovary, non-Hodgkin lymphoma, myeloma and cervix cancer (adjustment by BMI and age was a positive determinant for these cancer types ). Unsurprisingly, age differences may also affect the outcome ( Table 5 ). The limited analyses on follow up time were inconclusive. Male gender was a significantly negative determinant of risk of leukemia, which was in accordance with the fact that risk of leukemia was increased in female diabetes patients (RR= 1.45, 95% CI 1.06-1.99) and only slightly increased in male diabetes patients (RR= 1.12, 95% CI 1.00-1.26).
From the present literature, it was impossible to distinguish the cancer risk between T1D and T2D. Only a single study report of T1D [39] , whereas some studies report of T2D. Some of the studies classified as diabetes unspecified in Table 1 -3 claim to report only of T2D, however exclude T1D by age at diagnosis: excluding diabetes diagnosed at younger age than 18 [45] , 20 [97] , 21 [56] , 25 [65] or 30 [68, 71, 115, 139] . Nevertheless, the investigated population may consist of both T1D and T2D.
Diabetes ascertainment and cancer ascertainment (available in the electronic Supplementary Material 2) varied between studies and may, based on the meta-regression, be a determinant of the study outcome. Whether the study was hospital or population based may also affect the outcome ( Table 5 ). These methodological differences, which may bias the results, raise the question of the necessity of uniform standards to reduce bias. In general the study quality did not determine the outcome of the pooled analysis (Table 5) , however study quality based on NOS score was a significantly negative determinant risk of lung cancer and a significantly positive determinant of prostate cancer; meaning that the risk ratios drew closer towards 1 for both cancers. Adjustment for the NOS score only changed the outcome little. Some publication bias was present, with an underreporting of non-significant results from small studies. This may also affect the outcomes. Also only published data as age and BMI were collected, whereas not all studies reported these factors. This may affect the results of the meta-regression. These restrictions and limitations may affect the results, but it is implausible to be the explanation of the increased risk of cancer among diabetes patients.
CONCLUSION
The present systematic review and meta-analysis confirms the previous findings of an increased cancer risk in diabetes and extends these findings to additional cancer types. The results indicate that the risk was not modified by obesity and was thus either due to diabetes per se or other confounders. Unfortunately, important covariates as HbA1c and duration of diabetes were not available in a sufficient number of studies. It is thus difficult to determine whether the increased cancer risk was due to diabetes per se or other prognostic factors like anti-diabetic treatment.
Nevertheless, the clinical implications of this and previous studies are of importance. It is recommendable that physicians in contact with patients with diabetes are attentive to the increased cancer risk associated with diabetes. Whether the awareness should be aimed at a diabetes group receiving a specific treatment is unknown and the future results of the CARING project are awaited.
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